**TREATMENT OF PITYRIASIS VERSICOLOR AT THE PRESENT STAGE**

|  |  |
| --- | --- |
| **About the author:** | Ya.F. Kutasevych, I.O. Oliinyk, I.O. Mashtakova |
| **Heading** | CLINICAL OBSERVATIONS |
| **Type of article** | Scentific article |
| **Annotation** | **The objective** was to evaluate the therapeutic efficacy and tolerance of the naftifine hydrochloride spray in monotherapy of multicolored lichen.  **Materials and methods**. The study involved 30 patients with pityriasis versicolor. Of these, 18 men and 12 women, aged 19 to 65 years,  with a disease duration of 1 month to 5 years. Patients in complex treatment received a spray of Estesifin 1% (the active substance is naftifine hydrochloride) manufactured by Farmak JSC. Therapeutic efficacy was evaluated by the dynamics of the clinical manifestations of the disease and the results of mycological studies. Tolerance to the drug was evaluated by the presence of locally irritating and allergic reactions.  **Results**. When using Estesifin spray, patients noted a decrease in itching after the first application of the drug; relief of itching was noted on the 4th-5th day of treatment in 26 patients (13.3%). The available therapeutic effect was manifested in the resolution of erythematous-squamous elements, was detected on the 4th-5th day from the start of treatment in 24 patients (6.0%). Clinical recovery was observed in 28 patients (93.3%) on (15.8 ± 1.6) day of treatment, mycological negativity – in 100% of patients (14.0 ± 0.3) day of treatment. Patients noted the convenience in using the spray, which was manifested in the use of the drug once a day. The skin did not sweat, it quickly dried up after applying a preparation that did not leave marks on the linen. All this affected compliance in treatment. None of the patients showed locally irritating effects and allergic reactions.  **Conclusions.** The drug Estesifin Spray, containing 1% naftifine hydrochloride, has a pronounced therapeutic effect (93.3%) in the treatment of multi-colored lichen, promotes rapid clinical (at (15.8 ± 1.6) day) and mycological (at (14.0 ± 0.3) days) recovery of patients.The drug has good tolerance, optimal consumer properties and high compliance. |
| **Tags** | malassesia, multicolored lichen, naftifine hydrochloride spray |
| **Bibliography** | * 1. Albanova VI. Malasseziya: nedootsenennyiy obitatel kozhi cheloveka [Malassesia: the underrated inhabitant of human skin]. Immunopatologiya, allergologiya, infektologiya. 2017;2:24–31. 2. Veretelnik KA. Sovremennyie podhodyi k topicheskoy terapii malassezioza kozhi [Modern approaches to the topical treatment of malassesiosis of the skin]. Dermatovenerologiya. Kosmetologiya. Seksopatologiya. 2014;1–4:212–214. 3. Kravchenko VH, Horbuntsov VV, Bashmakov DH. Mozhlyvosti lokalnoi terapii piohennykh urazhen, poiednanykh z proiavamy malaseziozu na volosystii chastyni holovy [Possibilities of local therapy of pyogenic lesions combined with manifestations of malassesiosis on the scalp]. Dermatovenerolohyia. Kosmetolohyia. Seksopatolohyia. 2017;1–4:209–211. 4. Kutasevich Ya F. K voprosu ob atipichnyih formah mikozov gladkoy kozhi [To the question of atypical forms of smooth skin mycoses]. Dermatologiia ta venerologiia. 2015;4:96–101. 5. Ovchinnikov RS. Gribyi roda Malassezia v zabolevaniyah zhivotnyih: biologiya, ekologiya, patogenez, predraspolagayuschie faktoryi [Fungi of the genus Malassezia in animal diseases: biology, ecology, pathogenesis, predisposing factors]. VetPharma 2013; 1. http://vetpharma. org/articles/70/4683/. 6. Sergeev VYu, Burtseva GN, Baranova MO. Mestnaya terapiya onihomikozov – ot preventivnogo lecheniya k profilaktike reinfektsii [Topical treatment of onychomycosis – from preventive treatment to prevention of reinfection]. Immunopatologiya, allergologiya, infektologiya. 2017;4:65–72. 7. Faergemann J. Atopic dermatitis and fungi. J Clin Microbiol Rev. 2002;15(4):545–63. 8. Giusiano G. Prevalence of Malassezia specie in pityriasis versicolor lesions in Argentina. Revista Iberoamericana de Micologia. 2010;27(2):71–4. 9. Hort W, Mayser P. Malassezia virulence determinants. Curr Opin Infect Dis. 2011;24:100–105. 10. Karakas M. Epidemiology of Pityriasis Versicolor in Adana, Turkey. Journal of Dermatology. 2009;36:377–382. 11. Velegraki A, Cafarchia C, Gaitanis G, et al. Malassezia infections in humans and animals: pathophysiology, detection, and treatment. PLoS Pathog. 2015;11(1):e1004523. 12. Thayikkannu AB, Kindo AJ, Veeraraghavan M. Malassezia – can it be ignored? Indian J Dermatol. 2015;60(4):332–339. 13. Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The role of Malassezia spp. in atopic dermatitis. J Clin Med. 2015;29(4, 6):1217–1228. 14. Velegraki A, Cafarchia C. Gaitanis gassezia infections in humans and animals: pathophysiology, detection, and treatment. PLoS Pathog. 2015;11(1):e1004523. |
| **Publication of the article** | «DERMATOLOGY AND VENEREOLOGY» №1(87), 2020 year,21-25 pages,  index UDK  *616.992.282* |
| **DOI** | 10.33743/2308-1066-2020-1-21-25 |